Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zevra Therapeutics (ZVRA) Common Equity (2016 - 2025)

Historic Common Equity for Zevra Therapeutics (ZVRA) over the last 11 years, with Q3 2025 value amounting to $133.2 million.

  • Zevra Therapeutics' Common Equity rose 9086.28% to $133.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $133.2 million, marking a year-over-year increase of 9086.28%. This contributed to the annual value of $39.7 million for FY2024, which is 3588.19% down from last year.
  • Per Zevra Therapeutics' latest filing, its Common Equity stood at $133.2 million for Q3 2025, which was up 9086.28% from $117.2 million recorded in Q2 2025.
  • Over the past 5 years, Zevra Therapeutics' Common Equity peaked at $439.6 million during Q2 2023, and registered a low of $32.5 million during Q2 2024.
  • For the 5-year period, Zevra Therapeutics' Common Equity averaged around $175.4 million, with its median value being $117.2 million (2025).
  • As far as peak fluctuations go, Zevra Therapeutics' Common Equity surged by 41322.24% in 2022, and later crashed by 9261.19% in 2024.
  • Quarter analysis of 5 years shows Zevra Therapeutics' Common Equity stood at $127.1 million in 2021, then crashed by 40.91% to $75.1 million in 2022, then dropped by 17.65% to $61.9 million in 2023, then plummeted by 35.88% to $39.7 million in 2024, then surged by 235.72% to $133.2 million in 2025.
  • Its Common Equity was $133.2 million in Q3 2025, compared to $117.2 million in Q2 2025 and $41.0 million in Q1 2025.